The FDA has cleared Athenex's investigational new drug application for its autologous T cell receptor-T cell therapy TCRT-ESO-A2, which targets NY-ESO-1 positive solid tumors in human leukocyte antigen-A positive patients.
FDA clears Athenex's IND application for T-cell therapy
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.